0 rating

Congenital Heart Disease and Pulmonary Arterial Hypertension: Focus on Eisenmenger’s Syndrome

Julie Wacker and Maurice Beghetti, MD

Congenital heart disease (CHD), which has an incidence of eight new cases per 1000 live births, represents one of the most common groups of congenital malformations. Pulmonary arterial hypertension (PAH) is a serious and dreaded complication, and occurs in approximately 15% of patients with CHD [1]. In fact, more than half of the cases of PAH in children are secondary to CHD (PAH-CHD) [2,3].

Return to top


Pharmacotherapeutic Options for Pulmonary Arterial Hypertension
Myung H Park, MD
CML Pulmonary Hypertension
Endothelial Progenitor Cells as a Target for Therapy of Pulmonary Hypertension
Laszlo Farkas, MD1,2,3, and Martin R Kolb, MD, PhD1,2
CML Pulmonary Hypertension
Inflammatory Mechanisms 
in Pulmonary Hypertension
Ali Sadoughi, MD1,2, Yinzhong Zhang MD, PhD1, Edmund J Miller, PhD, FRSC1,3,4, and Arunabh Talwar, MD, FCC P1,2,3,4
CML Pulmonary Hypertension
Noninvasive Imaging in the Evaluation 
of Pulmonary Hypertension
Asghar A Fakhri, MD1, Vikas K Rathi, MD, FACC2, Rachel Hughes-Doichev, MD, FASE1, and Raymond L Benza, MD1
CML Pulmonary Hypertension
Sickle Cell Disease-Associated Pulmonary Hypertension: the Effect of Anemia and High Cardiac Output
Shoaib Alam, MD, and Gregory J Kato, MD
CML Pulmonary Hypertension